SCHEMBL4958636

SCHEMBL4958636

O=P(O)(O)CS(=O)(=O)N1CCN(c2ccc(Cl)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.46
CNR2 P34972 1/20 0.45
DRD2 P14416 5/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
DRD4 P21917 4/20 0.43
HTR1A P08908 2/20 0.43
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
HTR7 P34969 2/20 0.43
DRD3 P35462 2/20 0.43
TMEM97 Q5BJF2 2/20 0.43
SIGMAR1 Q99720 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PANK3 Q9H999 1/20 0.42
CHRM1 P11229 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155339 0.83 KDM4E (0.44) GPR119CNR2DRD2KDM4EALDH1A1
SCHEMBL4754484 0.80 GPR119 (0.54) GPR119CNR2DRD2KDM4EALDH1A1
SCHEMBL4958147 0.79 GPR119 (0.44) GPR119CNR2DRD2KDM4EALDH1A1
SCHEMBL2155345 0.78 GPR119 (0.44) GPR119CNR2DRD2KDM4EALDH1A1
SCHEMBL4958144 0.78 GPR119 (0.46) GPR119CNR2DRD2KDM4EALDH1A1
SCHEMBL2155271 0.77 GPR119 (0.59) GPR119CNR2ALDH1A1L3MBTL1PANK3
SCHEMBL7155176 0.75 PANK3 (0.44) GPR119DRD2KDM4EALDH1A1MAPT
SCHEMBL2959440 0.72 CHRM4 (0.66) GPR119ALDH1A1L3MBTL1CHRM1KMT2A
SCHEMBL16495544 0.72 DRD2 (0.42) GPR119DRD2DRD4HTR1AHTR2A
SCHEMBL941995 0.72 MMP7 (0.47) GPR119DRD2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
EP-1828160-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS LABORATOIRES SERONO S.A. (CH) 2007-09-05 EP disclosed
WO-2006067114-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS GPR119 80/4885CNR2 709/4885DRD2 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.